---
figid: PMC7179076__nihms-1548227-f0002
figtitle: Wild type (wt) p53 and mutant (mut) p53 expressed in tumor cells on anti-tumor
  immune responses and inflammation
organisms:
- Adenoviridae
- Betapolyomavirus macacae
- Murine leukemia virus
- Canarypox virus
- Homo sapiens
- Mus musculus
- Equus caballus
pmcid: PMC7179076
filename: nihms-1548227-f0002.jpg
figlink: /pmc/articles/PMC7179076/figure/F2/
number: F2
caption: Wt p53 upregulates MHC class I antigen presentation pathway and apoptosis
  receptors Fas/APO-1 and TRAILR1/2. In tumor cells lacking p53 or expressing p53mut,
  expression of MHC class I is low and PD-L1 high resulting in inhibition of the CTL
  upon binding to PD-1 receptor, whereas p53mut promotes upregulation of the NF-kB
  signaling, increased cytokine production and immune cell activation. In addition,
  activation of ROS induces the Jak-STAT signaling pathway, resulting in reduction
  of CD8+ T cells and increased immune cell frequencies. Furthermore, mut p53 cells
  shed miR-1246-enriched exosomes with a concomitant uptake by macrophages triggering
  immunosuppression. A variety of intracellular and extracellular signals induce senescent
  immune cells. CD8+CD28− T cells contribute to immune suppression and resistance
  to immunotherapy through several cytokines and changes in Δ133p53 and p53β expression.
papertitle: 'The p53 saga: Early steps in the development of tumor immunotherapy.'
reftext: Albert B. De Leo, et al. J Immunol. ;204(9):2321-2328.
year: '2020'
doi: 10.4049/jimmunol.1901343
journal_title: 'Journal of immunology (Baltimore, Md. : 1950)'
journal_nlm_ta: J Immunol
publisher_name: ''
keywords: ''
automl_pathway: 0.766735
figid_alias: PMC7179076__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Equus caballus
redirect_from: /figures/PMC7179076__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7179076__nihms-1548227-f0002.html
  '@type': Dataset
  description: Wt p53 upregulates MHC class I antigen presentation pathway and apoptosis
    receptors Fas/APO-1 and TRAILR1/2. In tumor cells lacking p53 or expressing p53mut,
    expression of MHC class I is low and PD-L1 high resulting in inhibition of the
    CTL upon binding to PD-1 receptor, whereas p53mut promotes upregulation of the
    NF-kB signaling, increased cytokine production and immune cell activation. In
    addition, activation of ROS induces the Jak-STAT signaling pathway, resulting
    in reduction of CD8+ T cells and increased immune cell frequencies. Furthermore,
    mut p53 cells shed miR-1246-enriched exosomes with a concomitant uptake by macrophages
    triggering immunosuppression. A variety of intracellular and extracellular signals
    induce senescent immune cells. CD8+CD28− T cells contribute to immune suppression
    and resistance to immunotherapy through several cytokines and changes in Δ133p53
    and p53β expression.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD28
  - CXCL8
  - IL6
  - TGFB1
  - TGFB2
  - TGFB3
  - FAS
  - FASN
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - TNFRSF10A
  - TNFSF10
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - STAT3
  - CD4
  - MIR1246
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - IL10
  - ITK
  - SLC22A3
  - CRYGC
  - CRYGEP
  - CCL1
  - CCL2
  - CCL3L1
  - CCL3L3
  - CCL4L1
  - CCL4L2
  - CCL5
  - CCL7
  - CCL8
  - CCL11
  - CCL13
  - CCL14
  - CCL15
  - CCL16
  - CCL17
  - CCL18
  - CCL19
  - CCL20
  - CCL21
  - CCL22
  - CCL24
  - CCL25
  - CCL26
  - CCL27
  - CCL28
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL9
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL16
  - CXCL17
  - XCL1
  - XCL2
  - CCL3
  - CCL4
  - S100A9
  - Cd28
  - Renbp
  - Cxcl15
  - Il6
  - Tgfb1
  - Ltbp1
  - Fas
  - Fasn
  - Jun
  - Tnfsf10
  - Cd274
  - Pdcd1
  - Stat3
  - Cd4
  - Nfkb1
  - Il10
  - Itk
  - Slc22a3
  - Ccl17
  - Cxcl5
  - S100a9
---
